EGFR and glioblastoma: Choi et al. report data from a prespecified interim analysis of the first 3 patients with IDH wild-type recurrent glioblastoma treated in the first-in-human, investigator-initiated, open-label INCIPIENT study.7 The innovative CAR-T cell construct CARv3-TEAM-E applied in this study targets EGFRvIII antigen, as well as the wild-type EGFR protein via secretion of a T-cell–engaging antibody molecule (TEAM).